Very excited to share our latest paper describing crosstalk between αvβ6 integrin & HER2 in breast cancer invasion & drug resistance. Great work by @HJMald & many others https://t.co/PdTG1XsPZE @ScienceAdvances @LivUniISMIB @AdamHurlstone Many thanks to @BCCare @NorthWestCancer

NEWS | New insights in breast cancer progression and drug resistance ➡️ https://t.co/c8mp9fx2kx #CancerResearch | #TeamLivUni

Look at the amazing speaker list for Adhere2 next September! This is going to be an excellent meeting, in beautiful Zadar, Croatia. https://t.co/o6u0LywicO

6) High levels of GDI2 expression correlate with better patient survival 7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

6) High levels of GDI2 expression correlate with better patient survival 7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

A particularly intriguing observation: Invasion of trastuzumab resistant cells is αVβ6-independent. But resistant cells express very high levels αVβ6 on the cell surface. Opening up opportunities to potentially target them with an αVβ6-targeting warhead, or immuno-modulator

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.

2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling. 3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.

We show that: 1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance

https://t.co/W2kB0u4drD

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.

2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling. 3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.

We show that: 1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance.

https://t.co/6CP5QCyNID

Very excited to share our new paper on Talin binding to Amyloid Precursor Protein indicating a new way to think about Alzheimer's Disease. It has the most provocative discussion section we have ever written :) https://t.co/MfJtvQ91Db

Excited to share that our latest paper on the crosstalk between integrin αVβ6 and HER2 in HER2+ breast cancer is OUT! @M_MorganLab @LivUniCancer @ScienceAdvances @LivUniISMIB #BreastCancer #Trastuzumab https://t.co/3GuMge62mP

Great to meet you face to face for the first time @M_MorganLab & thank you for a great talk @LivCancerRes #LCR121! So much opportunity for #collaboration in tumour micro-environment and #immuno-oncology studies across @LivUniISMIB @livuniHLS @livuninews @LivHPartners

Dr Muhammad Awais from @LivUniCancer brought pancreatic research to Liverpool College for a Role Model Day👩‍🔬encouraging year 5 pupils to consider a career in science! Lab coats & origami added fun and culture to the day🥼 https://t.co/4xTIaXxlte